Literature DB >> 18374999

Atrial fibrillation in chronic non-cardiac disease: where do we stand?

Mitja Lainscak1, Nikolaos Dagres, Gerasimos S Filippatos, Stefan D Anker, Dimitrios Th Kremastinos.   

Abstract

Atrial fibrillation is the most common arrhythmia, and is associated with increased risk of stroke and death. Most of present knowledge is derived from studies in patients with cardiac disease whilst limited information is available for patients with several chronic non-cardiac conditions like cancer, chronic obstructive pulmonary disease and chronic kidney disease. Although millions of patients are affected and are at risk of adverse prognosis due to co-existent atrial fibrillation, we are left with very limited guidance for management of atrial fibrillation itself and prevention of complications in those patients. In this paper, we review data on incidence, prognostic importance and treatment modalities of atrial fibrillation in patients with cancer, chronic obstructive pulmonary disease, and chronic kidney disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18374999     DOI: 10.1016/j.ijcard.2007.12.078

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  19 in total

1.  Chemotherapy-induced Cardiotoxicity.

Authors:  Maria Florescu; Mircea Cinteza; Dragos Vinereanu
Journal:  Maedica (Bucur)       Date:  2013-03

2.  Zoledronic acid and atrial fibrillation in cancer patients.

Authors:  Cagatay Arslan; Sercan Aksoy; Omer Dizdar; Didem S Dede; Hakan Harputluoglu; Kadri Altundag
Journal:  Support Care Cancer       Date:  2010-04-01       Impact factor: 3.603

3.  The burden of chronic obstructive pulmonary disease in patients hospitalized with heart failure.

Authors:  Mitja Lainscak; Lea Majc Hodoscek; Hans-Dirk Düngen; Mathias Rauchhaus; Wolfram Doehner; Stefan D Anker; Stephan von Haehling
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

4.  Ventricular arrhythmic disturbances and autonomic modulation after beating-heart revascularization in patients with pulmonary normotension.

Authors:  Jus Ksela; Jurij Matija Kalisnik; Viktor Avbelj; Piotr Suwalski; Grzegorz Suwalski; Borut Gersak
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

Review 5.  [Medicinal treatment of atrial fibrillation in special situations].

Authors:  Dietrich Pfeiffer; Daniel Jurisch; Jens-Gerrit Kluge; Andreas Hagendorff; Norbert Klein
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2014-02-18

6.  Colorectal cancer and risk of atrial fibrillation and flutter: a population-based case-control study.

Authors:  Rune Erichsen; Christian Fynbo Christiansen; Frank Mehnert; Noel Scott Weiss; John Anthony Baron; Henrik Toft Sørensen
Journal:  Intern Emerg Med       Date:  2011-10-04       Impact factor: 3.397

7.  The Associations of Atrial Fibrillation With the Risks of Incident Invasive Breast and Colorectal Cancer.

Authors:  Sylvia Wassertheil-Smoller; Aileen P McGinn; Lisa Martin; Beatriz L Rodriguez; Marcia L Stefanick; Marco Perez
Journal:  Am J Epidemiol       Date:  2017-03-01       Impact factor: 4.897

8.  A Prospective Study to Evaluate the Effect of Paclitaxel on Cardiac Ejection Fraction.

Authors:  Mohammed Osman; Mohammad Elkady
Journal:  Breast Care (Basel)       Date:  2017-08-29       Impact factor: 2.860

9.  Arrhythmias during and after zoledronic acid infusion patients with bone metastasis.

Authors:  Ozan Yazici; Sercan Aksoy; Ozgul Ucar; Nuriye Ozdemir; Mevlut Demir; Mehmet Ali Nahit Sendur; Zafer Arik; Sebnem Yaman; Tulay Eren; Dogan Uncu; Nurullah Zengin
Journal:  Med Oncol       Date:  2013-05-21       Impact factor: 3.064

Review 10.  Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention.

Authors:  Adriana Albini; Giuseppina Pennesi; Francesco Donatelli; Rosaria Cammarota; Silvio De Flora; Douglas M Noonan
Journal:  J Natl Cancer Inst       Date:  2009-12-10       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.